TrialCancer immunology, immunotherapy : CII2012

A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.

Theresa L Whiteside et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.